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PPaclitaxel-Eluting Coronary
Stents in Patients With Diabetes Mellitus
Pooled Analysis From 5 Randomized Trials
Ajay J. Kirtane, MD, SM,* Stephen G. Ellis, MD,† Keith D. Dawkins, MD,‡ Antonio Colombo, MD,§
Eberhard Grube, MD, Jeffrey J. Popma, MD,¶ Martin Fahy, MSC,* Martin B. Leon, MD,*
Jeffrey W. Moses, MD,* Roxana Mehran, MD,* Gregg W. Stone, MD*
New York, New York; Cleveland, Ohio; Southampton, United Kingdom; Milan, Italy; Siegburg, Germany;
and Boston, Massachusetts
Objectives We sought to examine the safety and efficacy of paclitaxel-eluting stents (PES) in patients with diabetes
mellitus (DM).
Background Compared with patients without DM, patients with DM undergoing percutaneous coronary intervention are at
increased risk for mortality and restenosis. The safety of drug-eluting stents in diabetic patients has recently
been called into question by a published meta-analysis of randomized trials.
Methods Patient-level data were pooled from 5 prospective, double-blind, randomized trials of PES versus bare-metal
stents (BMS) (n  3,513). Safety and efficacy outcomes through 4 years of follow-up were assessed among the
827 randomized patients (23.6%) with DM.
Results Patients treated with PES and BMS has similar baseline characteristics among both the diabetic and nondiabetic co-
horts within these trials. At 4-year follow-up, there were no significant differences between PES and BMS among dia-
betic patients in the rates of death (8.4% vs. 10.3%, respectively, p 0.61), myocardial infarction (6.9% vs. 8.9%,
p  0.17), or stent thrombosis (1.4% vs. 1.2%, p 0.92). Treatment of diabetic patients with PES compared with
treatment with BMS was associated with a significant and durable reduction in target lesion revascularization over
the 4-year follow-up period (12.4% vs. 24.7%, p 0.0001). The relative safety and efficacy of PES compared with the
relative safety and efficacy of BMS in diabetic patients extended to both those requiring and not requiring insulin.
Conclusions In these 5 randomized trials in which patients with single, primarily noncomplex lesions were enrolled, treat-
ment with PES compared with treatment with BMS was safe and effective, resulting in markedly lower rates
of target lesion revascularization at 4 years, with similar rates of death, myocardial infarction, and stent
thrombosis. (J Am Coll Cardiol 2008;51:708–15) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035o
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Gfter stent implantation, patients with diabetes mellitus
DM) are more likely to develop restenosis and require
epeat revascularization procedures compared with those
ithout DM (1), and are also at greater risk for stent
hrombosis (2), myocardial infarction (MI), and death (1,3).
lthough drug-eluting stents (DES) reduce angiographic
nd clinical restenosis compared with bare-metal stents
BMS) (4,5), late stent thrombosis has been reported to
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ates of death and MI are similar between DES and BMS
6–9). Whether DES are similarly safe and effective in the
igher risk cohort of diabetic patients remains controversial.
n particular, a recent meta-analysis of double-blind, ran-
omized trial data reported greater long-term mortality in
atients with DM treated with sirolimus-eluting stents
SES) compared with those treated with BMS, an effect
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February 19, 2008:708–15 Paclitaxel-Eluting Stents and DMhat was absent in patients without DM (7). A similar
nalysis with polymer-based paclitaxel-eluting stents (PES)
as not been undertaken.
Therefore, we sought to determine the long-term outcomes
f patients with and without DM from the 5 major double-
lind, prospective randomized trials of PES versus BMS.
ethods
tudy description. The databases from the prospective, mul-
icenter, double-blind, placebo-controlled randomized
AXUS-I (10), -II (11), -IV (5), -V (12), and -VI (13) trials
f PES versus BMS were pooled for a patient-level meta-
nalysis. These studies were chosen as they comprise the
nly double-blind randomized trials of PES versus BMS,
nd were utilized for regulatory approval in the U.S. and
uropean Union. The primary study comparison for this
nalysis was between the randomized treatment arms (PES
s. BMS) among both diabetic and nondiabetic patients.
urther analyses of PES versus BMS were conducted in the
27 diabetic patients in these studies to assess for differences
mong the subgroups of patients with insulin-dependent
iabetes mellitus (IDDM) and noninsulin-dependent dia-
etes mellitus (NIDDM).
In each trial, patients with a single de-novo lesion in a
ative coronary artery were prospectively assigned in equal
roportions to stent implantation with either a PES or an
therwise equivalent BMS (both Boston Scientific, Natick,
assachusetts), although the entry criteria, device specifi-
ations, and geography of study location varied somewhat
mong the trials, as outlined in Table 1. Each trial is still
linded with follow-up planned to 5 years, with neither the
atients, investigators, nor study personnel knowing which
tent individual subjects received. Overall, 72.1% of patients
n the study population underwent protocol-mandated an-
iographic follow-up (70.1% for patients with DM and
2.5% for patients without DM).
nd points and definitions. Target lesion revasculariza-
ion (TLR) and target vessel revascularization (TVR) were
xamined as clinical measures of stent efficacy. The follow-
ng end points were examined to assess stent safety: stent
hrombosis (as prospectively defined in the study protocols),
I (all, Q-wave, and non–Q-wave), death (all cause,
ardiac, and noncardiac), composite death or MI, composite
eath or Q-wave MI, and composite cardiac death or MI.
tent thrombosis data adjudicated by the Academic Re-
haracteristics of Included Trials
Table 1 Characteristics of Included Trials
Number
Randomized Geography Stent Platform Drug Release
TAXUS-I 61 Germany NIRx Slow
TAXUS-II 536 Global NIRx Slow and m
TAXUS-IV 1,314 U.S. Express Slow
TAXUS-V 1,156 U.S. Express2 Slow
TAXUS-VI 446 Europe Express ModerateRandomization to paclitaxel-eluting stent versus bare-metal stent was stratified by presence of diabetesearch Consortium (ARC) defi-
itions (14) were also available in
rials testing the slow-release ver-
ion of the PES (TAXUS-I,
AXUS-II SR [Slow Release],
AXUS-IV, and TAXUS-V).
ata from the original databases
s prospectively defined and ad-
udicated by the clinical events
ommittees for each individual
tudy were used in the present
nalysis (5,10–13).
tatistical analysis. Categorical
ariables were compared by chi-
quare or Fisher exact test. Con-
inuous variables are described as
ean  standard deviation and
ere compared by unpaired t
ests. At the time of this report,
ata were available for TAXUS-I
o 5 years, for TAXUS-II and
IV to 4 years, for TAXUS-VI to
years, and for TAXUS-V to 2
ears. Time-to-event data are re-
orted and displayed as Kaplan-
eier estimates for the primary
nalyses, with comparisons be-
ween groups by the log-rank test (or exact log-rank test
henever there were 5 observations for any end point).
azard ratios (HRs) derived from univariate Cox models
or the comparisons between PES and BMS are also
isplayed. Analyses were truncated at 4 years of follow-up
ue to the small number of patients with available data
hereafter. All analyses are by intention-to-treat, with all
atients randomized to each stent included. Tests for
eterogeneity of treatment effect across these studies dem-
nstrated no significant heterogeneity with regards to the
nd points of death, MI, stent thrombosis, TLR, or TVR.
dditionally, first-order tests of interaction terms for pri-
ary end points were conducted according to diabetic status
vs. nondiabetic status) as well as according to insulin-
equirement. An alpha of 0.05 was used for statistical
ignificance. All analyses were performed by an academic
tatistician at the Cardiovascular Research Foundation
M.F.) without sponsor involvement.
Abbreviations And
Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
DM  diabetes mellitus
HR  hazard ratio
IDDM  insulin-dependent
diabetes mellitus
MI  myocardial infarction
NIDDM  noninsulin-
dependent diabetes
mellitus
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ics
Percentage of Patients
With Diabetes
Reference Vessel
Diameter (mm) Lesion Length (mm)
11 (18.1%) 3.0 to 3.5 12
e 58 (10.8%) 3.0 to 3.5 12
318 (24.2%)* 2.5 to 3.75 10 to 28
356 (30.8%)* 2.25 to 4.0 10 to 46
89 (20.0%) 2.5 to 3.75 18 to 40at baseline.Kinet
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aseline and angiographic characteristics. The baseline
emographic and procedural characteristics of the random-
zed PES- and BMS-treated groups were well matched in
atients both with and without DM (Table 2), except for a
lightly higher prevalence of hyperlipidemia among diabetic
atients randomized to PES. Baseline angiographic charac-
eristics including reference vessel diameter (RVD) and
esion length were also similar among patients treated with
ES and BMS (Table 2).
Compared with patients without DM, patients with DM
ere older, more likely to be women, and more frequently
ad concomitant cardiovascular risk factors such as hyper-
ension and hyperlipidemia. Patients with DM also had
maller treated vessels (mean RVD 2.64 vs. 2.77 mm, p 
.001) and longer treated lesions (15.9 vs. 14.8 mm,
 0.002), with a greater number of stents used (1.25 vs.
.18, p  0.001) and longer overall stent length (25.6 vs.
3.9 mm, p  0.002) compared with nondiabetic patients.
fficacy end points. At 4 years in the entire study popu-
ation, patients with DM compared with those without DM
ad higher rates of TLR (18.6% vs. 14.1%, p  0.005) and
VR (27.3% vs. 19.2%, p  0.001). As seen in Table 3 and
igures 1 and 2, the use of PES compared with BMS
esulted in marked reductions in ischemic TLR both in
atients with DM (HR 0.42 [95% confidence interval (CI)
.30 to 0.60]) and without DM (HR 0.47 [95% CI 0.38 to
.59]). The use of PES also reduced ischemic TVR inde-
endent of diabetic status (HR 0.67 [95% CI 0.50 to 0.89]
n patients with DM and 0.61 [95% CI 0.51 to 0.73] in
atients without DM). The magnitude of the reductions in
LR and TVR was similar among patients with and
aseline Demographic and Angiographic Characteristics
Table 2 Baseline Demographic and Angiographic Characteristic
No D
PES (n  1,347)
Median follow-up, days (interquartile range) 1,401 (1,079, 1,449)
Age (yrs) 62.18 11.00
Women 24.4% (328/1,347)
Insulin-dependent diabetes —
Current smoker 25.3% (338/1,337)
Hypertension 65.9% (887/1,347)
Hyperlipidemia 68.3% (915/1,339)
Target coronary artery
Left anterior descending 41.9% (562/1,340)
Left circumflex 24.2% (324/1,340)
Right 33.4% (447/1,340)
Pre-reference vessel diameter 2.77 0.49 (1,333)
Pre-lesion length 14.78 7.62 (1,332)
Pre-minimal luminal diameter 0.91 0.34 (1,334)
Pre-diameter stenosis (%) 67.0 10.7 (1,334)
Number stents implanted 1.19 0.46 (1,339)
Total stent length 23.9 10.8 (1,331)
nless otherwise indicated, numbers in parentheses indicate the number of patients. All p  NS b
f hyperlipidemia between PES and BMS in diabetic patients.
DM  diabetes mellitus.ithout DM (all p for interaction  NS). In patients both
ith and without DM, the difference in clinical restenosis
ates in the 2 randomized study arms peaked by 1 year and
hen remained stable through 4 years (Fig. 1).
afety end points. At 4 years in the entire study popula-
ion, patients with DM compared with those without DM
ad a higher rate of death (9.4% vs. 5.5%, p  0.001) and
trend toward a slightly higher rate of MI (7.9% vs. 6.3%,
 0.13), but similar rates of stent thrombosis (1.3% vs.
.0%, p  0.63). The rates of protocol-defined stent
hrombosis between PES and BMS were not significantly
ifferent at 4 years both in patients with DM (1.4% [4
vents] vs. 1.2% [5 events], p  0.92) and in patients
ithout DM (1.3% [16 events] vs. 0.8% [9 events], p 
.16) (Table 4). Among patients treated in the trials of the
low-release formulation of the PES compared with those
reated with BMS, there were no significant differences in
ates of overall ARC thrombosis or definite/probable
hrombosis in either diabetic patients or nondiabetic pa-
ients (Table 4). There were no significant differences in
he 4-year rates of all-cause mortality between PES and
MS in patients with DM (8.4% vs. 10.3%, respectively,
 0.61) or in patients without DM (5.4% vs. 5.5%, p 
.92); cardiac and noncardiac mortality rates were also
imilar. The 4-year rates of MI in patients treated with
ES and BMS were comparable in diabetic patients
6.9% vs. 8.9%, p  0.17) and nondiabetic patients (7.1%
s. 5.6%, p  0.17), without differences in rates of
-wave or non–Q-wave MI. The rates of composite end
oints (death or MI, cardiac death or MI, and all-cause
eath or Q-wave MI) were also similar in PES-treated
nd BMS-treated patients with and without DM. The
DM
MS (n  1,339) PES (n  408) BMS (n  419)
,407 (1,080, 1,452) 1,102 (867.5, 1,439) 1,109 (968, 1,442)
.95 10.63 63.15 10.29 62.80 10.32
.7% (344/1,339) 38.2% (156/408) 32.5% (136/419)
— 31.1% (127/408) 32.9% (138/419)
.4% (325/1,333) 18.5% (75/405) 18.3% (76/416)
.1% (842/1,335) 80.9% (330/408) 83.3% (349/419)
.8% (943/1,332) 77.8% (315/405) 70.2% (294/419)
.0% (561/1,335) 42.3% (171/404) 40.5% (169/417)
.8% (305/1,335) 29.7% (120/404) 27.3% (114/417)
.5% (460/1,335) 28.0% (113/404) 31.7% (132/417)
.77 0.51 (1,325) 2.64 0.55 (406) 2.64 0.50 (417)
.90 7.98 (1,330) 16.13 8.60 (403) 15.57 7.91 (416)
.92 0.37 (1,331) 0.88 0.38 (404) 0.89 0.35 (417)
6.8 11.6 (1,331) 66.9 11.7 (404) 66.5 11.2 (417)
.17 0.44 (1,333) 1.26 0.54 (407) 1.23 0.50 (419)
3.8 11.0 (1,320) 26.0 12.3 (404) 25.2 11.7 (413)
paclitaxel-eluting stents (PES) and bare-metal stents (BMS) except for p  0.01 for comparisons
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February 19, 2008:708–15 Paclitaxel-Eluting Stents and DMffects of PES versus BMS upon the occurrence of any of
he individual safety end points were additionally similar
hen stratified by diabetic status (all p for interaction  NS).
utcomes in IDDM versus NIDDM. Patients with
DDM compared with those with NIDDM were more
ften women (40.4% vs. 32.9%, p  0.042); the baseline
emographic and procedural characteristics were otherwise
omparable between the 2 groups. In addition, the pre-
rocedural RVD, lesion length, total stent length, and
-Year Efficacy Outcomes
Table 3 4-Year Efficacy Outcomes
No DM
Efficacy End Points PES BMS HR (95% CI)
TLR 9.5% (122) 18.6% (241) 0.47 (0.38–0.59)
PTCA 8.5% (108) 16.2% (212) 0.48 (0.38–0.61)
CABG 1.1% (14) 3.1% (39) 0.35 (0.19–0.65)
TVR 15.3% (191) 23.1% (294) 0.61 (0.51–0.73)
PTCA 13.3% (165) 20.2% (259) 0.60 (0.49–0.73)
CABG 2.2% (28) 4.3% (52) 0.53 (0.34–0.84)
alues are displayed as Kaplan-Meier estimate rates (number of events).
CABG coronary artery bypass grafting; CI confidence interval; HR hazard ratio; PTCA pe
evascularization; other abbreviations as in Table 2.
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Figure 1 Diabetes
Kaplan-Meier estimates representing the 4-year cumulative rates of death (top lef
and target lesion revascularization (bottom right) for the pooled randomized trials
The number of patients at risk for each year is provided, equal to the number of pumber of stents implanted were similar among patients
ith IDDM and NIDDM (data not shown).
The magnitude of reduction in ischemic TLR was similar
mong patients with IDDM and NIDDM (Table 5) (p for
nteraction 0.93). Despite a significant reduction in TLR with
ES compared with that in BMS in patients with IDDM (12.5%
s. 22.9%, p  0.009), the 4-year rates of TVR were similar
26.4% vs. 27.0%, p  0.66). Ischemic TVR was reduced in
atients with NIDDM assigned to PES (23.8% vs. 31.7%, p 
DM
Value PES BMS HR (95% CI) p Value
0.0001 12.4% (44) 24.7% (97) 0.42 (0.30–0.60) 0.0001
0.0001 11.9% (42) 19.5% (78) 0.52 (0.35–0.75) 0.0004
0.0005 0.5% (2) 6.3% (22) 0.09 (0.02–0.39) 0.0001
0.0001 24.4% (81) 30.2% (115) 0.67 (0.50–0.89) 0.005
0.0001 18.7% (66) 23.7% (92) 0.70 (0.51–0.96) 0.025
0.006 6.5% (17) 8.8% (29) 0.59 (0.33–1.08) 0.083
ous transluminal coronary angioplasty; TLR target lesion revascularization; TVR target vessel
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Paclitaxel-Eluting Stents and DM February 19, 2008:708–15.002). Nonetheless, there was no significant interaction between
DDM and NIDDM as regards the treatment effect of PES in
educing TVR (p for interaction  0.16).
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Figure 2 No Diabetes
Kaplan-Meier estimates representing the 4-year cumulative rates of death (top lef
and target lesion revascularization (bottom right) for the pooled randomized trials
tus. The number of patients at risk for each year is provided, equal to the number
-Year Safety Outcomes
Table 4 4-Year Safety Outcomes
No DM
Safety End Points PES BMS HR (95% C
Death 5.4% (58) 5.5% (59) 0.98 (0.68–1
Cardiac death 1.9% (21) 2.7% (28) 0.75 (0.43–1
Noncardiac death 3.6% (37) 2.9% (31) 1.19 (0.74–1
MI 7.1% (87) 5.6% (70) 1.24 (0.91–1
Q-wave 1.6% (20) 1.0% (11) 1.82 (0.87–3
Non–Q-wave 5.7% (69) 4.7% (61) 1.13 (0.80–1
Stent thrombosis
Per protocol* 1.3% (16) 0.8% (9) 1.77 (0.78–4
ARC (all)† 3.6% (33) 4.0% (33) 1.00 (0.62–1
ARC (definite/probable)† 2.1% (20) 1.6% (15) 1.33 (0.68–2
Death or MI 11.9% (139) 10.5% (123) 1.13 (0.89–1
Cardiac death or MI 8.6% (104) 7.8% (93) 1.12 (0.85–1
Death or Q-wave MI 6.8% (75) 6.3% (68) 1.11 (0.80–1
alues are displayed as Kaplan-Meier estimate rates (number of events). *Per-protocol definit
evascularization; †these data were available only from patients in the trials testing the slow-release vers
ARC  Academic Research Consortium definitions; MI  myocardial infarction; other abbreviations asRates of stent thrombosis, all-cause mortality, cardiac
eath, and noncardiac death were similar among patients
reated with PES versus BMS irrespective of IDDM or
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cardial infarction (top right), protocol-defined stent thrombosis (bottom left),
litaxel-eluting stents versus bare-metal stents in patients without diabetes melli-
ients with follow-up at each time period less those with earlier events.
DM
p Value PES BMS HR (95% CI) p Value
0.92 8.4% (28) 10.3% (33) 0.88 (0.53–1.45) 0.61
0.31 4.0% (15) 3.7% (14) 1.10 (0.53–2.28) 0.80
0.47 4.5% (13) 6.8% (19) 0.71 (0.35–1.44) 0.34
0.17 6.9% (24) 8.9% (35) 0.70 (0.41–1.17) 0.17
0.11 0.5% (2) 1.5% (6) 0.34 (0.07–1.70) 0.26
0.49 6.4% (22) 7.3% (29) 0.77 (0.45–1.35) 0.36
0.16 1.4% (4) 1.2% (5) 0.83 (0.22–3.09) 0.92
1.00 4.8% (15) 3.1% (11) 1.38 (0.63–3.00) 0.42
0.40 2.2% (6) 1.4% (5) 1.22 (0.37–4.01) 0.74
0.31 14.1% (48) 16.2% (60) 0.81 (0.56–1.19) 0.28
0.43 9.8% (35) 10.7% (43) 0.83 (0.53–1.29) 0.40
0.55 8.8% (30) 11.8% (39) 0.79 (0.49–1.27) 0.33
stent thrombosis do not count thrombosis events occurring after an intervening target lesionNumb
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f Q-wave MI among PES-treated patients with NIDDM
ompared with that seen in patients with IDDM (0.4% vs.
.3%, p  0.10), although Q-wave MI occurred relatively
nfrequently in this group of patients (7 total events). There
ere no differences in the 4-year composite rates of death or
I, death or Q-wave MI, or cardiac death or MI between
ES and BMS in patients with IDDM or in patients with
IDDM (Table 5).
iscussion
he principal findings from this patient-level pooled meta-
nalysis of patients with single, de-novo coronary lesions
nrolled in the 5 prospective double-blind, randomized
rials of PES versus BMS through 4-year follow-up are:
) treatment with PES rather than BMS resulted in marked
eductions in ischemic TLR in both patients with and
ithout DM; 2) the rates of stent thrombosis, MI, and
eath were comparable with PES and BMS throughout the
ollow-up period in both patients with and without DM;
nd 3) the relative safety and efficacy profile of PES
ompared with those seen with BMS in patients with DM
xtended to both those requiring and not requiring insulin.
fficacy of PES in diabetic patients. As expected, patients
nrolled in the TAXUS trials in whom DM was present had
igher rates of revascularization at 4 years than those seen in
atients without DM. The present analysis also demon-
trates a marked reduction in ischemic TLR and TVR with
ES compared with that seen with BMS at 4 years in both
iabetic and nondiabetic patients. These results are consis-
ent with the primary mechanism of PES in reducing
fficacy and Safety Outcomes Among Diabetic Patients According
Table 5 Efficacy and Safety Outcomes Among Diabetic Patient
NIDDM
PES BMS HR (95%
Efficacy end points
TLR 12.2% (31) 25.5% (67) 0.42 (0.27–0
PTCA 11.8% (30) 18.7% (50) 0.56 (0.36–0
CABG 0.4% (1) 8.5% (20) 0.05 (0.01–0
TVR 23.8% (51) 31.7% (80) 0.58 (0.41–0
PTCA 18.1% (44) 22.8% (59) 0.71 (0.48–1
CABG 6.6% (9) 10.5% (24) 0.37 (0.17–0
Safety end points
Death 6.3% (15) 8.0% (18) 0.84 (0.43–1
Cardiac death 3.1% (8) 2.2% (6) 1.33 (0.46–3
Noncardiac death 3.3% (7) 6.0% (12) 0.60 (0.23–1
MI 6.9% (17) 8.0% (22) 0.76 (0.41–1
Q-wave 0.4% (1) 2.3% (6) 0.17 (0.02–1
Non–Q-wave 6.5% (16) 5.7% (16) 1.00 (0.50–1
Stent thrombosis (per protocol) 0.7% (2) 1.4% (4) 0.50 (0.09–2
Death or MI 11.9% (29) 14.7% (38) 0.75 (0.46–1
Cardiac death or MI 8.7% (22) 9.8% (27) 0.80 (0.46–1
Death or Q-wave MI 6.6% (16) 10.3% (24) 0.66 (0.35–1
alues are displayed as Kaplan-Meier estimate rates (number of events).
IDDM  insulin-dependent diabetes mellitus; MI  myocardial infarction; NIDDM  noninsulin-eointimal hyperplasia after stent implantation. While the maximal difference between PES and BMS in TLR oc-
urred by 1 year (and in absolute terms may have been
omewhat exaggerated due to the performance of angio-
raphic follow-up in a subset of patients in these studies)
15), there was no late catch-up observed even among the
ohort with DM. However, consistent with prior studies
emonstrating that progression of disease remote from the
arget lesion is the cause of the majority of subsequent
evascularizations in patients with DM (1), the difference in
VR rates between PES and BMS narrowed somewhat
etween 3 and 4 years in the diabetic cohort (although
emaining significantly different). This finding was espe-
ially evident in patients with insulin-requiring DM, in
hom there was no difference in TVR at 4 years between
ES and BMS, despite a marked reduction in TLR with
ES. This may have resulted from more rapid progression
f native atherosclerosis in insulin-requiring compared with
oninsulin-requiring diabetic patients.
The early impact of PES in reducing restenosis compared
ith BMS is consistent with prior studies with follow-up to
year (16,17). The persistent benefit of PES in our study
eyond this period, however, contrasts with the findings
ecently reported from the observational T-SEARCH
Taxus-Stent Evaluated At Rotterdam Cardiology Hospi-
al) registry, in which the benefit of PES compared with
hat of BMS was attenuated over 2-year follow-up in
ropensity-adjusted analyses (18). As a “real-world registry,”
-SEARCH enrolled more complex patients than those in
he trials included in the present meta-analysis. Though the
resent study results, comprised of patient-level data from
sulin-Dependent Status
ording to Insulin-Dependent Status
IDDM
p Value PES BMS HR (95% CI) p Value
0.0001 12.5% (13) 22.9% (30) 0.43 (0.22–0.82) 0.009
0.012 11.8% (12) 21.2% (28) 0.43 (0.22–0.84) 0.011
0.0001 0.8% (1) 1.7% (2) 0.54 (0.05–5.95) 0.61
0.002 26.4% (30) 27.0% (35) 0.90 (0.55–1.46) 0.66
0.079 19.9% (22) 25.3% (33) 0.69 (0.40–1.18) 0.17
0.008 6.8% (8) 5.2% (5) 1.74 (0.57–5.33) 0.32
0.623 12.7% (13) 15.0% (15) 0.93 (0.44–1.95) 0.85
0.59 6.0% (7) 7.0% (8) 0.95 (0.34–2.62) 0.92
0.27 7.1% (6) 8.6% (7) 0.91 (0.30–2.70) 0.86
0.40 7.0% (7) 10.8% (13) 0.58 (0.23–1.45) 0.23
0.10 0.8% (1) 0.0% (0) N/A 0.96
0.99 6.2% (6) 10.8% (13) 0.49 (0.19–1.29) 0.14
0.60 2.7% (2) 0.7% (1) 2.13 (0.19–23.53) 0.71
0.25 18.6% (19) 19.2% (22) 0.92 (0.50–1.70) 0.79
0.44 12.0% (13) 12.8% (16) 0.87 (0.42–1.82) 0.72
0.20 13.5% (14) 15.0% (15) 1.01 (0.49–2.09) 0.99
ent diabetes mellitus; other abbreviations as in Tables 2 and 3.to In
s Acc
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enefits of PES in higher-risk patients.
The long-term durable benefit of PES in terms of
nhancing freedom from repeat revascularization in patients
ith and without DM is similar to that reported in a recent
eta-analysis from the 4 principal randomized trials of SES
ersus BMS (7). Randomized and registry studies examin-
ng the relative efficacy of PES and SES in patients with
M have reported conflicting results (16,18–26). Thus, an
dequately powered randomized trial is required to appro-
riately address this issue.
afety of PES in diabetic patients. In the present study,
he 4-year mortality rates were approximately doubled in
atients with versus without DM. As such, antirestenosis
herapies for patients with DM are required that ideally
ould reduce mortality, or at least not negatively impair
urvival while enhancing freedom from revascularization. In
his regard it is noteworthy that at 4 years the rates of
ortality in diabetic patients treated with PES were numer-
cally but not significantly lower than those seen in patients
reated with BMS, with similar rates of stent thrombosis
bserved with both stents. The relative safety profile of PES
n this regard was comparable in diabetic patients requiring
nd not requiring insulin. While these data should be
egarded cautiously given limited power to detect differences
n low-frequency safety events, this is the largest comparison
o date of PES versus BMS in DM patients using random-
zed clinical trial data. These findings, thus, can provide
arly reassurance that PES is not associated with significant
afety concerns in diabetic patients.
The present data contrast with the recently reported
ooled patient-level analysis of diabetic patients enrolled in
he 4 major prospective, double-blind randomized trials of
he polymer-based SES versus BMS (7). In the study by
paulding et al. (7) of 428 diabetic patients from the
AVEL (Randomized Comparison of a Sirolimus-Eluting
tent With a Standard Stent for Coronary Revasculariza-
ion), SIRIUS (Sirolimus-Eluting Stent in Coronary Le-
ions), C-SIRIUS (Canadian Sirolimus-Eluting Stent in
oronary Lesions), and E-SIRIUS (European and Latin
merican Sirolimus-Eluting Stent in Coronary Lesions)
rials, treatment with SES rather than BMS was associated
ith greater mortality during the 4-year follow-up period
12.2% vs. 4.4%, p  0.004), with a small excess of very late
tent thrombosis seen among this cohort of patients (11 vs.
events). The finding of higher mortality among SES-
reated patients in this analysis may have been due to
etter-than-expected survival among the diabetic patients
reated with BMS in these 4 trials and/or spurious results
ue to the modest-sized diabetic cohort (n  428) in this
eries. Nonetheless, with data from 827 randomized pa-
ients with DM to examine in the present patient-level
ooled meta-analysis of the TAXUS trials, it is reassuring
hat the 4-year mortality rate was numerically lower in
atients with diabetes treated with PES compared that seen
n patients treated with BMS (8.4% vs. 10.3%), with similar iumbers of patients experiencing stent thrombosis (4 vs. 5,
espectively).
tudy strengths and limitations. The relatively infrequent
ccurrence of death, MI, and stent thrombosis as well as the
imited number of diabetic patients studied in these trials
even when pooled) are insufficient to produce tight CIs
round these low event rates, and, thus, this analysis should
e viewed as hypothesis-generating. However, the upper
ound of the CI for the hazard of PES compared with BMS
s regards 4-year death or MI was 1.19, and, as such, it is
nlikely that a major safety issue exists. Additionally, the
resent analysis applies only to the types of patients, lesions,
nd stent platforms studied within these 5 randomized trials
i.e., single discrete de-novo native coronary arterial lesions
n relatively stable ischemic syndromes). The rates of both
fficacy and safety end points may vary in a more unselected
atient population in which stents are implanted in more
omplex and higher-risk situations, such as in true bifurca-
ion lesions, multivessel disease, and acute MI. This analysis
dditionally incorporated trials of both the commercial slow
ate-release formulation of PES as well as the noncommer-
ialized moderate rate-release formulation that releases
ore paclitaxel. However, no major clinical differences have
een described between these 2 versions in comparative
tudies (11).
Finally, the control arm in these trials was BMS rather
han coronary artery bypass graft surgery or medical therapy,
nd, as such, the performance of PES compared with the
erformance of these 2 therapeutic alternatives in diabetic
atients is unknown. Given the similar infarct-free survival
ates between PES and BMS in the present study, it is
nlikely that PES would be shown to reduce death or MI
ompared with optimal medical therapy in diabetic patients
ith stable angina (27). However, freedom from angina,
edication use, and rehospitalization for unplanned revas-
ularization would also be expected to be significantly
reater with PES than as recently described for BMS
ompared with more conservative medical treatment (27).
ngoing large-scale randomized trials are also underway to
etermine the relative safety and efficacy of DES compared
ith that of bypass graft surgery in patients with diabetes
nd multivessel disease.
onclusions
he present study demonstrates that with follow-up to 4
ears, treatment of single de-novo native coronary artery
esions with PES rather than BMS results in sustained
fficacy in reducing clinical restenosis among diabetic pa-
ients, with no apparent safety concerns evident. The
mphasis for future trials should thus shift to investigating
hrough appropriately powered randomized trials whether
here are true differences between different DES in patients
ith (and without) diabetes, establishing the safety and
fficacy of DES in more complex lesions than those studied
n the randomized trials to date, and studying the relative
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lternatives of medical therapy and bypass graft surgery in
imple and complex patients with and without DM.
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